数位生物标记市场按成分、生物标记类型、功能、治疗领域、应用和最终用户划分——2025-2030 年全球预测

预计 2024 年数位生物标记市场价值将达到 21.3 亿美元，2025 年将成长至 23.6 亿美元，到 2030 年将达到 39.6 亿美元，复合年增长率为 10.80%。

主要市场统计数据
基准年2024年	21.3亿美元
预计2025年	23.6亿美元
预测年份 2030	39.6亿美元
复合年增长率（%）	10.80%

引领数位生物标记成为个人化医疗和临床洞察创新的变革力量

随着数位生物标记物重新定义病患监测、诊断和治疗发展的格局，医疗保健产业正在经历一场根本性的变革。透过先进的感测器、穿戴式装置和植入式装置捕捉生理和行为数据，这些新指标使临床医生能够持续评估健康状况，而非仅进行单一评估。从依赖间歇性实验室测量和成像的传统生物标记物向数位生物标记物的演变，代表着疾病检测、追踪和治疗方式的范式转移。

开启下一波创新浪潮：技术进步与监管突破塑造数位生物标誌物的未来

由于技术突破、监管环境的演变以及患者期望的变化，数位生物标记领域正在发生重大变化。感测器小型化和功率效率的突破性改进扩大了可在临床环境之外捕获的生理讯号范围。穿戴式装置即时数据收集能够持续监测生命征象、活动模式和睡眠指标，为早期疗育和更精准的治疗方法创造了机会。

评估 2025 年美国关税政策对数位生物标记开发中供应链弹性和组件筹资策略的连锁反应

美国新关税的实施，为数位生物标记设备及组件的开发商和製造商带来了挑战和机会。进口感测器、微电子产品和先进材料面临关税上调，迫使他们调整筹资策略和供应链配置。为此，企业正在探索替代采购途径，并实现供应商组合多元化，以缓解成本压力。

透过多方面的组成部分、功能和治疗重点来剖析数位生物标记生态系统

透过多角度检验数位生物标记物生态系统，我们发现了六个关键的细分标准，每个标准都提供了对市场动态和技术发展轨蹟的细緻洞察。组件分析揭示了硬体和软体的二分法，硬体进一步分为植入、感测器和穿戴式设备，后者又细分为健身手环和智慧型手錶。这种差异凸显了感测器外形规格如何影响健身保真度和使用者采用率：小型智慧型手錶装置非常适合持续的生理监测，而消费性穿戴装置则优先考虑易用性和参与度。

绘製区域采用差异图，凸显全球数位生物标记市场的监管协调与创新丛集

反映多样化法律规范、医疗基础设施和投资格局的区域动态将在塑造数位生物标记物的采用和成熟度方面发挥关键作用。在美洲，北美创新中心凭藉科技公司与医疗服务提供者之间的紧密伙伴关係引领潮流，而拉丁美洲市场正在探索试验计画，以将远端监控能力扩展到资源匮乏的地区。该地区正在强调以患者为中心的价值提案，加速报销对话，并塑造新的医疗服务模式。

介绍透过策略合作和技术融合推进数位生物标记整合的主要企业

主要企业正在製定策略路径，以保持其领先地位，并加速将数位生物标记物整合到主流医疗保健领域。科技巨头们正在透过收购专注于感测器的新兴企业以及与数据分析公司合作来扩展其设备组合，以增强人工智慧能力。现有的医疗设备公司正在将数位终端整合到现有平台中，从而提高临床试验数据的粒度，并实现远端患者参与。

透过互通性、病人参与和供应链弹性保持竞争优势的策略要点

产业领导者必须采取多管齐下的策略，充分利用数位生物标记机会，并驾驭日益复杂的生态系统。投资符合新兴资料交换标准的互通平台，将简化与电子健康记录和分析工具的集成，从而加快洞察获取速度。与监管机构合作，优先考虑严格的验证框架，将确保数位终端符合临床试验和报销要求，从而促进更广泛的认可。

透过初步访谈、文献分析和数据三角测量相结合的方式，获得全面的数位生物标记洞察

本分析综合了严谨的混合方法研究途径的成果。主要研究涉及对 50 多位相关人员的深入访谈，包括设备製造商、软体开发商、医疗保健提供者和监管专家。这些访谈揭示了目前的验证实践、商业化策略以及应用障碍。

将数位生物标记创新与协作框架结合，为医疗保健转型规划道路

数位生物标记代表技术创新与临床需求的融合，为改善患者照护、简化药物开发和转变医疗服务模式提供了前所未有的机会。持续感知、高级分析和以患者为中心的设计的融合正在重新定义健康状况的监测、疾病的诊断和治疗的最佳化方式。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 整合人工智慧，提高数位生物标记的准确性和预测能力
• 开发用于早期检测神经退化性疾病的新型数位生物标记物
• 合作与伙伴关係激增，推动数位生物标记创新
• 开发心理健康数位生物标记物，用于客观评估和治疗反应
• 扩大数位生物标记在远端患者监护的应用，以改善慢性病管理
• 扩大法规结构将加速数位生物标记技术的核准和采用
• 实施区块链技术，实现安全透明的数位生物标记数据管理
• 精准医疗中数位生物标记的日益普及将使客製化治疗计划成为可能
• 结合生理和行为数据的多模态生物标记的进展
• 扩展穿戴式设备，实现健康指标的持续即时监测

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：数位生物标记市场（按组成部分）

• 硬体
  • 植入
  • 感应器
  • 穿戴式装置
    • 健身带
    • 智慧型手錶
• 软体

第九章：数位生物标记市场（依生物标记类型）

• 积极的
• 被动的

第十章 数位生物标记市场：功能

• 经常使用
• 事件驱动
• 定期

第 11 章：按治疗领域分類的数位生物标记市场

• 心臟病学
  • 心律不整
  • 心臟衰竭
• 内分泌学
  • 糖尿病
  • 甲状腺疾病
• 神经病学
  • 阿兹海默症
  • 帕金森氏症
• 肿瘤学
  • 乳癌
  • 摄护腺癌
• 呼吸系统医疗设备

第 12 章：数位生物标记市场（按应用）

• 疾病诊断
• 药物开发
• 病患监测

第 13 章：数位生物标记市场（按最终用户）

• 学术研究机构
• 生技公司
• 医院和诊所
• 製药公司

14. 美国数位生物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 欧洲、中东和非洲数位生物标记市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16. 亚太数位生物标记市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • ActiGraph, LLC
  • Adherium Limited
  • Altoida, Inc.
  • Amgen Inc.
  • Aural Analytics, Inc. by Linus Health, Inc.
  • Biofourmis Pte. Ltd.
  • Biogen Inc.
  • Brainomix Limited
  • Eli Lilly and Company
  • Empatica Inc.
  • F. Hoffmann-La Roche Ltd.
  • Feel Therapeutics Inc.
  • GERO PTE. LTD.
  • Huma Therapeutics Limited
  • ICON PLC
  • IXICO PLC
  • Koneksa Health Inc.
  • Medable Inc.
  • Owkin, Inc.
  • Sonde Health, Inc
  • Teva Pharmaceutical Industries Ltd.
  • Verily Life Sciences, LLC
  • VivoSense, Inc
  • Chugai Pharmaceutical Co., Ltd.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Digital Biomarkers Market was valued at USD 2.13 billion in 2024 and is projected to grow to USD 2.36 billion in 2025, with a CAGR of 10.80%, reaching USD 3.96 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.13 billion
Estimated Year [2025]	USD 2.36 billion
Forecast Year [2030]	USD 3.96 billion
CAGR (%)	10.80%

Navigating the Emergence of Digital Biomarkers as a Transformational Force in Personalized Healthcare and Clinical Insight Innovation

The healthcare sector is experiencing a fundamental shift as digital biomarkers redefine the landscape of patient monitoring, diagnostics, and therapeutic development. By capturing physiological and behavioral data through sophisticated sensors, wearables, and implantable devices, these novel indicators are enabling clinicians to assess health status continuously rather than episodically. The evolution from traditional biomarkers, which rely on intermittent laboratory measurements or imaging, to digital biomarkers represents a paradigm change in how diseases are detected, tracked, and treated.

In parallel, advancements in data analytics, machine learning algorithms, and cloud computing infrastructures have accelerated the ability to extract meaningful insights from high-volume, high-velocity streams of patient data. As a result, stakeholders across the healthcare continuum-from pharmaceutical companies to hospitals and research institutes-are integrating digital biomarkers into clinical trials, remote monitoring programs, and real-world evidence studies. This introduction presents the foundational concepts and underscores the transformative potential that digital biomarkers hold for enhancing patient outcomes, optimizing care pathways, and driving innovation within a more connected ecosystem.

Unveiling the Next Wave of Innovation: Technological Advances and Regulatory Breakthroughs Shaping the Future of Digital Biomarkers

The landscape of digital biomarkers is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing patient expectations. Breakthroughs in sensor miniaturization and power efficiency have expanded the range of physiological signals that can be captured outside clinical settings. Real-time data collection from wearable devices now enables continuous monitoring of vital signs, activity patterns, and sleep metrics, creating opportunities for early intervention and more adaptive treatment regimens.

At the same time, regulatory agencies have begun to recognize digital biomarkers as legitimate endpoints in clinical trials, paving the way for faster approvals and broader adoption. Harmonized guidelines are emerging that emphasize data quality, validation protocols, and patient privacy safeguards. This regulatory clarity is empowering software developers and device manufacturers to collaborate more confidently on integrated platforms, ensuring interoperability and compliance across jurisdictions.

Concurrently, patients are increasingly demanding personalized care experiences that reflect their lifestyles and preferences. The convergence of patient-centric design principles with advanced analytics is fostering the development of digital health ecosystems where individuals can actively participate in their treatment journeys. As these transformative elements converge, stakeholders must navigate the complex interplay of innovation, regulation, and user engagement to fully realize the promise of digital biomarkers.

Evaluating the Ripple Effects of 2025 US Tariff Policies on Supply Chain Resilience and Component Sourcing Strategies in Digital Biomarker Development

The implementation of new tariff measures in the United States has introduced challenges and opportunities for developers and manufacturers of digital biomarker devices and components. Imported sensors, microelectronics, and advanced materials now face increased duties, which has led to shifts in sourcing strategies and supply chain configurations. In response, companies are exploring alternate procurement channels and diversifying supplier portfolios to mitigate cost pressures.

These tariff-induced dynamics have accelerated investments in domestic manufacturing capabilities, reducing reliance on cross-border shipments and enhancing supply chain resilience. Emerging partnerships between hardware producers and contract manufacturers are focusing on localizing production hubs, incorporating lean manufacturing techniques, and optimizing component designs to minimize reliance on high-cost imports. In parallel, some stakeholders have begun redesigning device architectures to utilize semiconductors and sensor modules that are exempt from elevated duties, ensuring continued innovation while preserving cost efficiencies.

Ultimately, while the cumulative impact of tariff policy has created short-term adjustments, it has also stimulated a strategic realignment toward more agile, vertically integrated operations. Companies that can adapt swiftly to these evolving trade parameters will be better positioned to deliver next-generation digital biomarker solutions with greater responsiveness to market demands.

Dissecting the Digital Biomarker Ecosystem Through Multifaceted Component, Functionality, and Therapeutic Focus Lenses

In examining the digital biomarker ecosystem through a multidimensional lens, six primary segmentation criteria emerge, each offering nuanced insights into market dynamics and technological trajectories. Component analysis reveals a dichotomy between hardware and software, with hardware further delineated into implantables, sensors, and wearables; the latter grouping subdivides into fitness bands and smartwatches. This distinction underscores how sensor form factors influence data fidelity and user adoption, with smaller implantable devices suited for continuous physiological monitoring and consumer-grade wearables prioritizing ease of use and engagement.

Biomarker types bifurcate into active indicators, which require user engagement or specific stimuli to generate data, and passive indicators that capture signals without direct patient interaction. This differentiation shapes the design of monitoring protocols and informs validation strategies for clinical integration. Functionality segmentation highlights continuous monitoring applications that track health metrics in real time, event-driven models that trigger data capture upon detecting predefined thresholds, and periodic assessments conducted at scheduled intervals. Each modality aligns with different clinical objectives, from chronic disease management to acute event detection.

Applications extend across disease diagnostics, where digital signatures complement traditional tests; drug development programs that employ sensor-derived endpoints to assess therapeutic efficacy; and patient monitoring initiatives that facilitate remote care pathways. End users encompass academic and research institutes pioneering exploratory studies, biotechnology firms driving product innovation, hospitals and clinics integrating digital data into care delivery, and pharmaceutical companies seeking to enrich clinical trials with real-world evidence. Therapeutic areas of focus include cardiology-addressing arrhythmia and heart failure-endocrinology tackling diabetes mellitus and thyroid disorders, neurology with emphasis on Alzheimer's and Parkinson's diseases, oncology concentrating on breast and prostate cancers, and pulmonology monitoring respiratory function. Together, these layers of segmentation reveal the complexity of stakeholder needs and technological opportunities driving digital biomarker advancement.

Mapping Regional Adoption Variances Highlighting Regulatory Harmonization and Innovation Clusters Across Global Digital Biomarker Markets

Regional dynamics play a pivotal role in shaping the adoption and maturation of digital biomarkers, reflecting diverse regulatory frameworks, healthcare infrastructures, and investment landscapes. In the Americas, innovation hubs in North America lead the charge with robust partnerships between technology firms and healthcare providers, while Latin American markets explore pilot programs to extend remote monitoring capabilities across under-resourced areas. This region's emphasis on patient-centric value propositions is accelerating reimbursement dialogues and forging new care delivery models.

Across Europe, the Middle East, and Africa, regulatory convergence initiatives are fostering harmonized data governance standards, enabling cross-border clinical studies and streamlined device approvals. Western European nations are integrating digital biomarkers into national health systems, leveraging public-private collaborations to scale remote care, whereas emerging markets in the region are prioritizing low-cost sensor solutions tailored to local epidemiological profiles. In parallel, nascent digital health consortia in select Middle East and African countries are focusing on capacity building and infrastructure development.

In the Asia-Pacific, rapid digitalization, strong government support for smart healthcare initiatives, and high smartphone penetration rates are driving widespread adoption of wearable-based monitoring. Local manufacturers are optimizing production costs and customizing devices to regional biometrics, while cross-industry alliances are developing ecosystem platforms that integrate hospital networks, insurers, and technology providers. The varied pace of regulatory maturity across the region underscores the need for adaptive market entry strategies.

Profiling Leading Organizations Advancing Digital Biomarker Integration Through Strategic Alliances and Technology Convergence

Key companies are forging strategic pathways to maintain leadership and accelerate the integration of digital biomarkers into mainstream healthcare. Technology giants are expanding their device portfolios through acquisitions of specialized sensor startups and forming alliances with data analytics organizations to bolster artificial intelligence capabilities. Established medical device firms are embedding digital endpoints into legacy platforms, enhancing clinical trial data granularity and enabling remote patient engagement.

Biotechnology innovators are leveraging strategic partnerships with contract research organizations to validate digital endpoints in early-phase studies, while software vendors are investing in cloud-native architectures to ensure scalability and interoperability with electronic health record systems. Collaborative ventures between pharmaceutical companies and sensor manufacturers are focusing on co-development agreements that align therapeutic protocols with adaptive monitoring solutions. Additionally, cross-sector consortia are being established to define industry standards, promote data sharing frameworks, and advance regulatory acceptance of sensor-based outcomes.

Strategic Imperatives for Maintaining Competitive Edge Through Interoperability, Patient Engagement, and Supply Chain Resilience

Industry leaders must adopt a multi-pronged approach to capitalize on digital biomarker opportunities and navigate an increasingly complex ecosystem. Investing in interoperable platforms that adhere to emerging standards for data exchange will streamline integrations with electronic health records and analytical tools, reducing time to insight. Prioritizing rigorous validation frameworks in collaboration with regulatory bodies will ensure that digital endpoints meet clinical trial and reimbursement requirements, fostering broader acceptance.

Cultivating patient-centric design practices, including co-creation workshops with end users, will enhance device usability and long-term engagement. Leaders should also pursue partnerships across the healthcare value chain-from payors to contract research organizations-to co-develop outcome-based models that demonstrate the real-world impact of digital biomarkers. Building resilient supply chains through diversified sourcing and on-shore manufacturing capabilities will mitigate risks associated with trade policy fluctuations.

Finally, establishing robust data governance and privacy safeguards will protect patient trust and align with global regulations. By integrating these strategic imperatives, organizations can drive sustainable growth, deliver enhanced clinical insights, and unlock new value propositions in digital health.

Combining Primary Interviews, Literature Analysis, and Data Triangulation to Derive Comprehensive Digital Biomarker Insights

This analysis synthesizes insights derived from a rigorous mixed-methods research approach. Primary research included in-depth interviews with over 50 stakeholders spanning device manufacturers, software developers, healthcare providers, and regulatory experts. These conversations elucidated current validation practices, commercialization strategies, and perceived barriers to adoption.

Secondary research involved a comprehensive review of peer-reviewed journals, technical white papers, and regulatory guidance documents to ensure factual accuracy and contextual relevance. Industry databases and public filings were examined to trace recent partnerships and technology integrations, while case studies provided practical examples of digital biomarker deployment in clinical and real-world settings. All data underwent cross-validation through triangulation techniques to reinforce credibility and mitigate potential biases.

The resulting insights reflect a holistic understanding of technological trends, policy influences, and stakeholder priorities shaping the digital biomarker landscape today.

Synthesizing Digital Biomarker Innovations and Collaborative Frameworks to Chart a Course for Healthcare Transformation

Digital biomarkers represent a convergence of technological innovation and clinical necessity, unlocking unprecedented opportunities to enhance patient care, streamline drug development, and transform healthcare delivery models. The integration of continuous sensing, advanced analytics, and patient-centric design is redefining how health status is monitored, diseases are diagnosed, and therapies are optimized.

As regulatory frameworks evolve and stakeholder collaborations deepen, the potential for digital biomarkers to become standard components in clinical protocols grows ever more tangible. Organizations that embrace interoperable infrastructure, robust validation processes, and adaptive business models will be poised to lead the next wave of digital health innovation. The insights presented in this summary lay the groundwork for strategic decision-making, offering a roadmap to navigate a rapidly changing ecosystem and realize the full promise of sensor-driven healthcare transformation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Integration of artificial intelligence to enhance digital biomarker accuracy and predictive capabilities
• 5.2. Development of novel digital biomarkers for early detection of neurodegenerative diseases
• 5.3. Surging collaborations and partnerships to advance digital biomarker innovation
• 5.4. Development of digital biomarkers for mental health for objective assessment and treatment response
• 5.5. Expanding use of digital biomarkers in remote patient monitoring to improve chronic disease management
• 5.6. Growing regulatory frameworks accelerating approval and adoption of digital biomarker technologies
• 5.7. Implementation of blockchain technology for secure and transparent digital biomarker data management
• 5.8. Rising adoption of digital biomarkers in personalized medicine for tailored treatment plans
• 5.9. Advancements in multi-modal digital biomarkers combining physiological and behavioral data
• 5.10. Expansion of wearable devices enabling continuous real-time monitoring of health metrics

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Digital Biomarkers Market, by Component

• 8.1. Introduction
• 8.2. Hardware
  • 8.2.1. Implantables
  • 8.2.2. Sensors
  • 8.2.3. Wearables
    • 8.2.3.1. Fitness Bands
    • 8.2.3.2. Smartwatches
• 8.3. Software

9. Digital Biomarkers Market, by Biomarker Type

• 9.1. Introduction
• 9.2. Active
• 9.3. Passive

10. Digital Biomarkers Market, by Functionality

• 10.1. Introduction
• 10.2. Continuous
• 10.3. Event-Driven
• 10.4. Periodic

11. Digital Biomarkers Market, by Therapeutic Area

• 11.1. Introduction
• 11.2. Cardiology
  • 11.2.1. Arrhythmia
  • 11.2.2. Heart Failure
• 11.3. Endocrinology
  • 11.3.1. Diabetes Mellitus
  • 11.3.2. Thyroid Disorders
• 11.4. Neurology
  • 11.4.1. Alzheimer's Disease
  • 11.4.2. Parkinson's Disease
• 11.5. Oncology
  • 11.5.1. Breast Cancer
  • 11.5.2. Prostate Cancer
• 11.6. Pulmonology

12. Digital Biomarkers Market, by Application

• 12.1. Introduction
• 12.2. Disease Diagnostics
• 12.3. Drug Development
• 12.4. Patient Monitoring

13. Digital Biomarkers Market, by End User

• 13.1. Introduction
• 13.2. Academic & Research Institutes
• 13.3. Biotechnology Firms
• 13.4. Hospitals & Clinics
• 13.5. Pharmaceutical Companies

14. Americas Digital Biomarkers Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Digital Biomarkers Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Digital Biomarkers Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. ActiGraph, LLC
  • 17.3.2. Adherium Limited
  • 17.3.3. Altoida, Inc.
  • 17.3.4. Amgen Inc.
  • 17.3.5. Aural Analytics, Inc. by Linus Health, Inc.
  • 17.3.6. Biofourmis Pte. Ltd.
  • 17.3.7. Biogen Inc.
  • 17.3.8. Brainomix Limited
  • 17.3.9. Eli Lilly and Company
  • 17.3.10. Empatica Inc.
  • 17.3.11. F. Hoffmann-La Roche Ltd.
  • 17.3.12. Feel Therapeutics Inc.
  • 17.3.13. GERO PTE. LTD.
  • 17.3.14. Huma Therapeutics Limited
  • 17.3.15. ICON PLC
  • 17.3.16. IXICO PLC
  • 17.3.17. Koneksa Health Inc.
  • 17.3.18. Medable Inc.
  • 17.3.19. Owkin, Inc.
  • 17.3.20. Sonde Health, Inc
  • 17.3.21. Teva Pharmaceutical Industries Ltd.
  • 17.3.22. Verily Life Sciences, LLC
  • 17.3.23. VivoSense, Inc
  • 17.3.24. Chugai Pharmaceutical Co., Ltd.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. DIGITAL BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. DIGITAL BIOMARKERS MARKET: RESEARCHAI
• FIGURE 28. DIGITAL BIOMARKERS MARKET: RESEARCHSTATISTICS
• FIGURE 29. DIGITAL BIOMARKERS MARKET: RESEARCHCONTACTS
• FIGURE 30. DIGITAL BIOMARKERS MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. DIGITAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY IMPLANTABLES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSORS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FITNESS BANDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SMARTWATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACTIVE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PASSIVE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CONTINUOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY EVENT-DRIVEN, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PERIODIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ARRHYTHMIA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 95. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 111. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 112. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 113. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 114. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 115. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 116. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 117. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 118. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 119. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 120. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 121. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 131. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 133. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 134. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 135. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 136. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 137. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 138. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 139. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 140. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 141. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 142. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 143. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 144. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 145. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 147. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 148. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 149. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 150. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 151. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 152. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 153. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 154. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 155. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 156. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 157. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 158. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 159. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 160. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 161. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 162. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 163. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 164. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 165. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 166. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 167. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 168. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 169. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 170. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 171. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 172. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 173. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 174. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 175. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 176. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 177. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 178. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 179. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 180. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 181. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 182. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 183. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 184. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 185. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 186. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 187. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 188. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 189. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 190. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 191. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 193. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 194. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 195. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 197. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 198. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 199. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 200. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 201. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 202. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 203. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 204. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 205. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 206. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 207. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 208. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 209. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 210. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 211. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 212. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 213. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 214. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 215. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 217. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 218. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 219. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 221. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 222. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 223. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 224. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 225. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 226. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 227. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 228. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 229. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 230. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 231. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 232. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 233. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 234. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 235. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 236. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 237. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 238. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 239. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 241. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 242. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 243. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 271. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 272. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 273. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 274. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 276. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 278. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 280. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 282. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 284. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 286. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 288. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 290. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 292. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 293. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 294. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 295. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 296. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 297. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 298. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 299. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 300. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 301. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 302. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 303. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 304. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 305. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 306. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 307. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 308. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 309. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 310. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 311. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 312. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 313. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 314. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 315. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 316. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 317. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 318. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 319. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 320. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 321. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 322. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 323. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2018-2024 (USD MILLION)
• TABLE 324. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLES, 2025-2030 (USD MILLION)
• TABLE 325. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
• TABLE 326. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025-2030 (USD MILLION)
• TABLE 327. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2018-2024 (USD MILLION)
• TABLE 328. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY FUNCTIONALITY, 2025-2030 (USD MILLION)
• TABLE 329. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 330. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
• TABLE 331. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
• TABLE 332. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOLOGY, 2025-2030 (USD MILLION)
• TABLE 333. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2024 (USD MILLION)
• TABLE 334. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ENDOCRINOLOGY, 2025-2030 (USD MILLION)
• TABLE 335. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
• TABLE 336. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGY, 2025-2030 (USD MILLION)
• TABLE 337. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 338. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
• TABLE 339. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 340. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 341. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 342. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 343. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
• TABLE 344. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
• TABLE 345. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
• TABLE 346. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
• TABLE 347. RUSS